8-bromo-7-methoxychrysin

8-Bromo-7-Methoxychrysin (BrMC): A Comprehensive Reference

1. Identity and Chemical Characterisation

Nomenclature and Structure

8-Bromo-7-methoxychrysin, universally abbreviated in the scientific literature as BrMC, is a semi-synthetic halogenated flavone. It is not found in nature and has no independent occurrence in food, honey, propolis, or plant material; it exists solely as a laboratory-synthesised compound. 8-bromo-7-methoxychrysin (BrMC) is a synthetic derivative of chrysin. BrMC has a molecular weight of 347 g/mol.

Its chemical name, parsed by its IUPAC-style descriptor, indicates that the molecule is derived from chrysin (the parent flavone) by two structural modifications: (1) a bromine atom introduced at position 8 of the chromone ring, and (2) a methoxy group (–OCH₃) substituted at position 7, replacing the 7-hydroxyl group present in the parent compound. These substitutions are deliberate medicinal chemistry improvements aimed at augmenting biological potency, metabolic stability, and membrane permeability relative to chrysin.

The Parent Compound: Chrysin

Understanding BrMC requires knowledge of its natural lead molecule. Chrysin, also known as 5,7-dihydroxy-2-phenyl-4H-chromene-4-one or 5,7-dihydroxyflavone, is a naturally occurring flavonoid with a backbone made of 15 carbon atoms. Chemically, chrysin belongs to the class of dihydroxyflavones, characterised by hydroxyl groups attached solely to the aromatic A-ring — specifically at the 5 and 7 positions — distinguishing it from other flavones.

Chrysin is a flavone found in honey, propolis, the passion flowers Passiflora caerulea and Passiflora incarnata, and in Oroxylum indicum. It is a naturally occurring compound extracted from various plants, including Passiflora caerulea (blue passionflower), Passiflora incarnata (purple passionflower), Oroxylum indicum, Cytisus multiflorus, Crataegus oxyacantha, Pelargonium crispum, Scutellaria immaculata, and Alpinia oxyphylla. Additionally, chrysin is found in different types of honey and propolis, as well as in certain edible mushrooms such as Pleurotus ostreatus (oyster mushroom).

The amounts of chrysin in natural matrices are modest. The amount of chrysin in honey from various plant sources is about 0.2 mg per 100 g. Chrysin is typically found at higher amounts in propolis than in honey. A 2010 study found the amount of chrysin was 0.10 mg/kg in honeydew honey and 5.3 mg/kg in forest honeys, while chrysin in propolis was found at as much as 28 g/L.

Rationale for Synthetic Modification

Poor oral bioavailability has been a major limitation for the successful use of dietary flavonoids as cancer chemotherapeutic agents. It has been reported that chrysin halogenated derivatives had stronger bioactivities than the lead compound. The higher hepatic metabolic stability and intestinal absorption of the methylated polyphenols make them more favourable than the unmethylated polyphenols for development as potential cancer chemopreventive agents.

Low aqueous solubility, rapid metabolism mediated by UGTs and SULT, and efficient excretion through efflux transporters including BCRP and MRP2 are the major reasons causing poor systemic bioavailability for chrysin. The introduction of a bromine atom at C-8 (halogenation) and a methoxy group at C-7 (O-methylation) into the chrysin scaffold was designed to address these limitations, producing BrMC as a compound with enhanced pharmacokinetic properties and amplified potency at the cellular level.

Forms and Preparations

BrMC is not commercially available as a dietary supplement in finished consumer products in the conventional sense. It exists exclusively as a research-grade synthetic chemical, synthesised in laboratory settings according to previously reported protocols referenced across the peer-reviewed literature. BrMC was synthesised as described previously. In published studies, BrMC is typically prepared as a stock solution dissolved in dimethyl sulphoxide (DMSO) and then diluted into cell culture medium or administered in experimental animal models. There is no documented consumer supplement preparation, no standardised herbal extract form, and no approved pharmaceutical formulation for BrMC as of the available literature.

2. Traditional and Historical Use

BrMC itself has no traditional or historical use in any culture. As a fully synthetic compound that does not exist in nature, it has no documented use in traditional medicine, ethnobotany, or historical pharmacopoeia. It was first synthesised and characterised in a contemporary medicinal chemistry context in the early 2000s, with the earliest peer-reviewed research appearing in the scientific literature around 2010.

The parent compound chrysin, however, is historically associated with traditional plant preparations. Chrysin is a flavone found in honey, propolis, and the passion flowers, and is extracted from various plants such as the blue passion flower (Passiflora caerulea). Passiflora incarnata, one of chrysin's botanical sources, has a long history of use in Native North American and European herbal traditions as an anxiolytic and sedative, though such traditional uses pertain to the whole-plant extract and its full complement of constituents — not to isolated chrysin or any derivative thereof. Any attribution of traditional use to BrMC based on its parent compound's botanical history would be scientifically unjustified.

3. Active Constituents and Established Mechanisms of Action

BrMC is itself the active molecule; it is not a botanical extract containing multiple constituents. Its documented biological activities derive from its structural interactions with specific intracellular signalling proteins and pathways. The following mechanisms have been reported in peer-reviewed preclinical research.

3.1 Caspase-Dependent Apoptosis via ROS Generation and JNK Activation

One of the earliest mechanistic studies of BrMC examined its apoptotic activity in human hepatocellular carcinoma (HCC) cells. Investigators sought to determine whether the apoptotic activities of BrMC involve reactive oxygen species (ROS) generation and c-Jun N-terminal kinase (JNK) activation in human hepatocellular carcinoma cells. Flow cytometry after propidium iodide staining showed a dose-dependent increase in the percentage of the sub-G1 cell population, reaching 39.0% ± 2.8% of HepG2 cells after 48 h of treatment with BrMC at 10 μmol/L. These results indicated that BrMC selectively induced apoptotic cell death of HCC cells in a caspase-dependent fashion.

BrMC elevated the level of phosphorylated JNK and phosphorylated c-Jun in a concentration-dependent manner and in a time-dependent manner. The antioxidant N-acetylcysteine (NAC) attenuated BrMC-induced ROS generation and reduced the induction of apoptosis in HepG2 cells, confirming that ROS production is mechanistically upstream of the apoptotic cascade triggered by BrMC.

3.2 Akt/FOXO3a Pathway Modulation

BrMC, a novel chrysin derivative, has been reported to have anti-cancer activities with more potent bioactivity than the lead compound. It has been proposed that BrMC-induced cell cycle arrest and apoptosis may be the mechanisms of its anticancer effects. In cisplatin-sensitive and cisplatin-resistant ovarian cancer cell models, BrMC-induced apoptotic cell death occurred mainly by the activation of Akt, which was accompanied by the overexpression of transcription factor FOXO3a, with a concomitant increase in the expression levels of Bim. The present study demonstrated that BrMC induced apoptotic cell death of cisplatin-sensitive and -resistant ovarian cancer cells in a dose-dependent manner and induced the release of cytochrome c in a time-dependent manner. The apoptotic effect of BrMC was found to be greater than that of chrysin, regardless of differences in chemosensitivity.

3.3 NF-κB Pathway Suppression

Nuclear factor kappa B (NF-κB) is a central transcription factor in inflammation and cancer cell survival. BrMC can effectually reverse the M2 polarisation of tumour-associated macrophages by inhibiting NF-κB activation. In lung cancer stem cell (CSC) models, BrMC and the NF-κB inhibitor SN50 alone or in combination could inhibit the expression of NF-κBp65 and FoxM1, sphere and colony formation, and the expression of CD133, CD44, Bmi1, and Oct4 in H460 cells induced by pro-inflammatory cytokines, whereas overexpression of NF-κBp65 almost abrogated the above effects of BrMC.

3.4 FoxM1 Suppression

Forkhead box transcription factor M1 (FoxM1) is a proto-oncogene involved in lung tumourigenesis. BrMC was found to suppress FoxM1 expression in lung cancer stem cells, and this suppression was cooperative with NF-κB inhibition. Overexpression of FoxM1 significantly compromised BrMC function on suppression of FoxM1 and NF-κBp65 as well as stemness of lung CSCs.

3.5 Wnt/β-Catenin Pathway Inhibition

In liver cancer stem cell (LCSC) studies, BrMC demonstrated the ability to downregulate β-catenin. Downregulation of β-catenin by BrMC resulted in inhibition of CSC function and characteristics of LCSCs, such as significant inhibition of proliferation and self-renewal, suppression of EMT and invasiveness, downregulation of the expression of stem cell markers of LCSCs, and further efficacious promotion of the elimination of LCSCs in vivo.

3.6 STAT3/Twist Axis Inhibition

Treatment with different concentrations of BrMC reduced the expressions of p-STAT3 and Twist1 proteins. The effect of BrMC was substantially enhanced by co-treatment with JSI-124, a specific inhibitor of STAT3. These results demonstrated that BrMC inhibits the stemness of liver cancer stem-like cells originated from the SMMC-7721 cell line by inhibiting the STAT3/Twist signal axis.

3.7 HER-2/neu Downregulation via Proteasomal Pathway

In HER-2/neu-overexpressing breast cancer models, it was demonstrated that BrMC preferentially inhibited the cell viability of HER-2/neu-overexpressing MDA-MB-453 and BT-474 cells. Western blot analysis revealed that HER-2/neu expression and tyrosine phosphorylation were inhibited by BrMC in a concentration-dependent manner, whereas the proteasome inhibitor MG-132 significantly prevented BrMC-induced HER-2/neu depletion and cell death in MDA-MB-453 cells, indicating that BrMC-induced HER-2/neu depletion and cell growth inhibition was mediated by a proteasomal pathway.

BrMC treatment suppresses the phosphorylation of PI3K/Akt and GSK-3β/β-catenin in HER-2/neu-overexpressing breast cancer cell lines.

3.8 Tumour-Associated Macrophage (TAM) Repolarisation

Beyond direct tumour-cell cytotoxicity, BrMC has been investigated for its effects on the tumour microenvironment. M2 polarisation of tumour-associated macrophages (TAMs) in the tumour microenvironment promotes liver cancer stem-like cell (LCSLC) self-renewal capability and carcinogenicity; therefore, reversing M2 polarisation of TAMs could be an effective approach to addressing HCC. Results showed that BrMC significantly suppressed the expression of the M2 macrophage marker CD163. BrMC may be a potentially novel flavonoid agent that can be applied for disrupting the interaction of LCSLCs and TAMs.

4. Scientific Evidence by Area of Use

Critical note on evidence quality: As will be described in each subsection, all published studies on BrMC are preclinical investigations conducted in cell culture (in vitro) or animal models (in vivo, primarily xenograft mouse models). No human clinical trials of BrMC have been published or registered. Several key papers from the primary research group at Hunan Normal University have additionally been retracted due to concerns over data integrity. These retractions materially affect the overall reliability of the literature base and are documented in the Safety section. Evidence across all areas is therefore to be characterised as preliminary, in-vitro/in-vivo preclinical only, and — given retractions — of uncertain integrity in several instances.

4.1 Hepatocellular Carcinoma (HCC) and Liver Cancer Stem Cells

The largest body of BrMC research concerns HCC. Multiple studies, predominantly from a single Chinese research group, examined its effects on HCC cell lines and liver cancer stem cell (LCSC) subpopulations.

In the foundational HCC apoptosis study (World J Gastroenterol, 2010), investigators aimed to determine whether the apoptotic activities of BrMC involve ROS generation and JNK activation in human HCC cells. HepG2, Bel-7402, and L-02 cell lines were cultured in vitro, and the apoptotic effects of BrMC were evaluated by flow cytometry after propidium iodide staining, caspase-3 activity using ELISA, and DNA agarose gel electrophoresis. BrMC induced dose-dependent apoptosis in malignant lines while its effects on normal embryo liver cells (L-02) were markedly lower, suggesting a degree of tumour selectivity at the concentrations tested.

In a 2013 study of liver cancer stem cells (LCSCs) derived from the MHCC97 cell line, investigators evaluated whether BrMC inhibits the properties of cancer stem cells derived from the human liver cancer MHCC97 cell line. CD133+ cells were sorted by magnetic activated cell sorting and amplified in stem cell-conditioned medium. The stem cell properties of CD133+ sphere-forming cells were validated by the tumorsphere formation assay in vitro and the xenograft nude mouse model in vivo. The conclusion was that BrMC can inhibit the functions and characteristics of LCSCs derived from the liver cancer MHCC97 cell line through downregulation of β-catenin expression.

Subsequent work from the same group on the SMMC-7721 HCC cell line investigated the STAT3/Twist axis. The sphere formation assay results showed a concentration-dependent decrease of sphere-forming capacity in liver cancer stem-like cells (LCSLCs) treated with different concentrations of BrMC. Ectopic expression of Twist1 attenuated the inhibitory effects of BrMC on sphere formation, migration, and expression of markers in LCSLCs, though it had no effect on p-STAT3 expression, demonstrating that BrMC inhibits the stemness of LCSLCs by inhibiting the STAT3/Twist signal axis.

The TAM repolarisation study investigated the effect of BrMC on M2 polarisation of macrophages activated by liver cancer stem-like cell conditioned medium. The current study revealed the pathomechanism by which the interaction of LCSLCs with hepatic stellate cells (HSCs) induces stemness of HCC cells via secreted high levels of IL-6 and HGF, and the pharmacological mechanism by which BrMC represses the secretion of IL-6 and HGF in conditioned medium, thereby blocking the interaction between LCSLCs and HSCs.

Evidence strength (HCC): Exclusively preclinical (in vitro and xenograft mouse models). No human data exist. Several studies from the primary contributing group have been retracted or flagged (see Section 7). Residual non-retracted studies remain preliminary.

4.2 Lung Cancer and Lung Cancer Stem Cells

BrMC's effects on lung cancer were investigated predominantly through the lens of cancer stem cells (CSCs) and the tumour microenvironment. The purpose of one study was to investigate whether BrMC inhibits lung cancer stemness of H460 cells induced by inflammatory factors (TGF-β combined with TNF-α) and its potential mechanism. Results showed that BrMC inhibited lung cancer stemness, as validated by enhanced self-renewal ability, higher in vitro tumorigenicity, and increased expression of CD133, CD44, Bmi1, and Oct4 in H460 cells administered TNF-α after prolonged induction by TGF-β, in a concentration-dependent manner.

Results suggested that activation of NF-κB and FoxM1 by cytokines facilitates the acquisition of the CSC phenotype and compromises chemical inhibition, which may represent an effective therapeutic target for treatment of human lung cancer.

Evidence strength (lung cancer): Exclusively preclinical, in-vitro cell-line work. The primary study on this topic was subsequently retracted (J Cancer 2022, retraction of the 2019 paper, DOI: 10.7150/jca.80863).

4.3 Colorectal and Gastric Cancer

Earlier work that established BrMC's superior potency relative to chrysin was conducted in colorectal and gastric cancer cell lines. The effect of BrMC on the inhibition of proliferation and induction of apoptosis in a colon cancer cell line HT-29 and a gastric cancer cell line SGC-7901 was stronger than that of chrysin. These findings, while widely cited as foundational justification for pursuing BrMC as a lead compound, were generated from in vitro cell-line experiments only.

Evidence strength (colorectal/gastric): Preliminary in vitro data only. No animal or human studies specific to colorectal or gastric cancer with BrMC alone were identified in the available peer-reviewed literature.

4.4 Ovarian Cancer (Including Cisplatin Resistance)

A notable area of BrMC research concerned its potential to overcome cisplatin resistance. The aim was to investigate the molecular mechanism of BrMC-induced apoptosis via the Akt/FOXO3a pathway in cisplatin-sensitive and -resistant ovarian cancer cells. The human ovarian cancer cell lines A2780 and A2780/DDP were cultured in vitro, and various molecular techniques were used to assess the expression of FOXO3a and Bim in cisplatin-sensitive and -resistant ovarian cancer cells. Different concentrations of BrMC induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. BrMC-induced apoptotic cell death occurred mainly by the activation of Akt, which was accompanied by the overexpression of transcription factor FOXO3a, with a concomitant increase in the expression levels of Bim.

Evidence strength (ovarian cancer): Exclusively in vitro cell-line study. This paper (Mol Med Rep 12: 5100–5108, 2015) was subsequently retracted in January 2026 due to concerns about western blot data integrity.

4.5 Breast Cancer (Including HER-2/neu-Overexpressing Subtypes)

BrMC's activity against HER-2/neu-overexpressing breast cancer cell lines was described in a study published in the journal Oncology Reports. It was unknown whether BrMC, a novel synthetic chrysin analog, inhibited the cell growth of HER-2/neu-overexpressing breast cancers. In the present study, it was demonstrated that BrMC preferentially inhibited the cell viability of HER-2/neu-overexpressing MDA-MB-453 and BT-474 cells. These data suggest that proteasomal activity was critically involved in BrMC-induced HER-2/neu degradation in MDA-MB-453 cells.

Evidence strength (breast cancer): Exclusively in vitro cell-line study. No animal or human data identified in the literature for this specific cancer type and BrMC.

5. Body Systems and Health Areas Associated with BrMC Research

• Hepatic / Liver System: Most extensively studied body system. Research covers HCC cell apoptosis, liver cancer stem cell properties, epithelial–mesenchymal transition (EMT) in liver tumour cells, and hepatic stellate cell interactions.
• Pulmonary / Respiratory System: Lung cancer stem cell biology, with focus on how inflammatory cytokines (TGF-β, TNF-α) interact with cancer stemness, and how BrMC may inhibit this process via NF-κB/FoxM1 suppression. Primary study in this area was retracted.
• Gynaecological / Reproductive System: Ovarian cancer, specifically investigating apoptosis in cisplatin-resistant cell lines. Primary study in this area was retracted.
• Mammary / Breast: HER-2/neu-overexpressing breast cancer cell biology and proteasome-mediated receptor downregulation.
• Gastrointestinal System: Early studies on colorectal (HT-29) and gastric (SGC-7901) cancer cell lines established BrMC's superior cytotoxic potency versus the parent chrysin compound.
• Immune System / Tumour Microenvironment: TAM polarisation research positions BrMC within immunomodulatory biology, specifically regarding the shift of pro-tumour M2-type macrophages through NF-κB pathway suppression.

6. Dosages Reported in Preclinical Studies

The following concentrations and doses are reported as used in published studies; they pertain exclusively to in vitro cell culture and in vivo rodent xenograft experiments. They do not constitute recommended human dosages and cannot be extrapolated to human therapeutic dosing due to the absence of pharmacokinetic, safety, or efficacy data in humans.

• In vitro HCC apoptosis (HepG2 cells): A dose-dependent increase in the sub-G1 cell population reached 39.0% ± 2.8% in HepG2 cells after 48 hours of treatment with BrMC at 10 μmol/L.
• In vitro lung cancer stem cells (H460): BrMC at 5.0 μmol/L and thiostrepton at 10.0 μmol/L alone or in combination significantly reduced expression of FoxM1 protein, accompanied by downregulation of NF-κBp65 expression.
• In vitro NF-κB/FoxM1 pathway (lung CSCs): The regulation on activation of NF-κB signalling and proto-oncogene FoxM1 were analysed by western blot in CSCs under different concentrations of BrMC (1, 5, 10 μM).
• In vitro liver cancer stem cells (MHCC97 β-catenin study): Comparative data was reported at 0.1 μmol/L BrMC or Wnt3a alone treated groups.
• In vitro HER-2/neu-overexpressing breast cancer cells (MDA-MB-453): MDA-MB-453 or BT-474 cells were incubated with or without BrMC (0–10 μM) or chrysin (50 μM) for 24 hours.
• In vivo (xenograft mouse): Multiple studies employed primary and secondary xenograft models in Balb/c-nu (nude) mice to test BrMC's effects on liver cancer stem cell elimination in vivo. Specific in vivo dose schedules were referenced in the published methods sections of those studies.

7. Safety Considerations, Data Integrity Issues, and Scientific Limitations

7.1 Absence of Human Safety and Toxicological Data

BrMC has not been evaluated in any human clinical trial, first-in-human pharmacokinetic study, dose-escalation trial, or toxicity assessment in humans. There are no published or registered Phase I, Phase II, or Phase III clinical trials for this compound. No regulatory submissions for BrMC as an investigational drug, dietary supplement, or compounded substance have been identified in the literature. Accordingly, the human safety profile of BrMC — including its maximum tolerated dose, off-target effects, drug interactions in humans, or safe exposure range — is entirely unknown.

7.2 Selectivity in Preclinical Models

In the hepatocellular carcinoma apoptosis study, BrMC was noted to induce apoptosis in malignant HCC cell lines (HepG2 and Bel-7402) while having a lower impact on L-02 normal human embryo liver cells at equivalent doses — a finding interpreted by the authors as suggestive of tumour selectivity. However, this in vitro finding has not been reproduced in intact animal toxicology or in human tissue.

7.3 Retractions and Data Integrity Concerns — Critical Notice

A significant proportion of the published literature on BrMC has been subjected to retraction or expression of editorial concern, representing a major qualification of the entire evidence base:

• Lung cancer / NF-κB / FoxM1 study (J Cancer 2019): The authors retracted their article (DOI: 10.7150/jca.30143), stating they could not revalidate the original western blot images since most authors had left the lab. They did not have the financial resources to repeat the experiments and all authors agreed to the retraction.
• Ovarian cancer / Akt / FOXO3a study (Mol Med Rep 2015): This paper was retracted (retraction published January 2026, DOI: 10.3892/mmr.2026.13796) following concerns raised by a reader about western blot data shown in the figures. The Editor apologised to the readership for any inconvenience caused.
• Liver cancer stem cell / hepatic stellate cell co-culture study (BMC Cancer 2019): The Editors retracted this article because of significant concerns with a number of figures, including panels that appeared duplicated across independent experimental conditions. The authors were contacted and asked for an explanation but did not provide one. The Editors therefore no longer have confidence in the integrity of the data in this article.

These retractions cluster around a single research institution (Hunan Normal University, Changsha, China) and a primary investigator group. While several other BrMC studies from adjacent groups remain in the literature, the systematic nature of the retractions across multiple cancer types and mechanistic claims means that any conclusion drawn from the BrMC literature must be treated with substantial caution pending independent replication.

7.4 No Established Drug–Drug Interactions

No clinical interaction studies exist for BrMC. As a flavone derivative, theoretical metabolic considerations would include potential interactions with cytochrome P450 enzymes and efflux transporters. Multiple metabolic enzymes (e.g., UGTs, SULTs, CYPs) and transporters (e.g., BCRP, MRP2/MRP4) are involved in chrysin's disposition. Whether analogous interactions apply to BrMC has not been established, as human pharmacokinetic data for BrMC do not exist.

7.5 Research Stage and Translational Gap

Although chrysin's biological activities have been demonstrated and the mechanism of actions has been determined using in vitro and in vivo models, results from the current clinical studies were largely negative. Given that the parent compound chrysin — which is a natural dietary constituent — has failed to demonstrate efficacy in human clinical trials largely due to poor bioavailability, the pathway from BrMC's preclinical findings to any validated therapeutic use in humans remains undefined. BrMC was designed in part to address chrysin's bioavailability limitations, but its human pharmacokinetic profile has never been characterised.

References

• Yang XH et al. 8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK. World J Gastroenterol 2010; 16(27):3385–3393. PMC2904884
• Quan MF et al. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin. World J Gastroenterol 2014; 19(43):7680–7690. PubMed PMID: 24431896
• 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin. PMC3837267
• 8-bromo-7-methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin-sensitive and resistant ovarian cancer cells. PMC4581817
• [Retracted] 8-bromo-7-methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin-sensitive and resistant ovarian cancer cells. Retraction Notice, Mol Med Rep. 2026. PMC12828304
• Inhibition of cell growth by BrMC through inactivation of Akt in HER-2/neu-overexpressing breast cancer cells. PMC3997727
• Luo Y et al. 8-Bromo-7-methoxychrysin-blocked STAT3/Twist axis inhibits the stemness of cancer stem cell-like cell originated from SMMC-7721 cells. Acta Biochim Biophys Sin 2017; 49(5):458–464
• Ren KQ et al. 8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling. PubMed PMID: 23970349
• Sun S et al. 8-bromo-7-methoxychrysin Reversed M2 Polarization of Tumor-associated Macrophages Induced by Liver Cancer Stem-like Cells. Bentham Science
• Retraction: 8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors. J Cancer 2022; 13(15):3716. PMC9809308
• Retraction Note: 8-bromo-7-methoxychrysin suppress stemness of SMMC-7721 cells induced by co-culture of liver cancer stem-like cells with hepatic stellate cells. BMC Cancer 2023. PMC10702102
• Chrysin. Wikipedia (citing primary literature sources on chrysin distribution and content in honey/propolis)
• Chrysin: A Comprehensive Review of Its Pharmacological Properties and Therapeutic Potential. Pharmaceuticals 2025. PMC12389306
• Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms. ResearchGate / TSU Digital Scholarship
• Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. ScienceDirect/Phytochemistry 2017
• Chrysin inhibits sphere formation in SMMC-7721 cells via modulation of SHP-1/STAT3 signaling pathway. Cancer Manag Res
• Yuan Q et al. 8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors. J Cancer 2019; 10(21):5244–5255 [subsequently retracted]
• 8-bromo-7-methoxychrysin suppress stemness of SMMC-7721 cells induced by co-culture of liver cancer stem-like cells with hepatic stellate cells. PMC6416872 [subsequently retracted]